Medicxi has closed Medicxi Fund V, a new €500 million vehicle focused on building and backing biotechnology companies with clearly defined product visions. The oversubscribed fund underscores continued investor appetite for the firm’s asset-centric approach to life sciences investing. With this close, Medicxi aims to accelerate the development of innovative therapies that address significant unmet medical needs and improve patient outcomes.
Fund Overview and Strategy
Fund V will continue Medicxi’s established strategy of creating and scaling asset-focused biotech companies rather than broad platform plays. The firm plans to deploy capital across the full drug development continuum, spanning company formation, early clinical studies and later stage development. This approach is designed to concentrate resources on high conviction assets, improve capital efficiency and shorten the path from scientific insight to tangible patient benefit.
Track Record and Portfolio Highlights
Since its previous fundraise, Medicxi has created 16 new companies and generated more than 20 positive clinical data readouts across its portfolio. The firm has realized over $1 billion from exits and value crystallization events, including stakes in Vaxcyte, Merus and Abivax, as well as the acquisitions of ViceBio by Sanofi, Versanis Bio by Eli Lilly and ProfoundBio by Genmab. These outcomes have reinforced confidence in Medicxi’s investment model and validated its ability to convert science into commercially and clinically meaningful products.
Investor Base and Capital Deployment Plans
Medicxi Fund V attracted strong support from existing limited partners alongside a select group of new institutional investors. The capital will be deployed both into newly created ventures and into existing portfolio companies that align with the firm’s asset-centric value creation thesis. By concentrating on focused programs and experienced drug hunters, Medicxi expects to maintain a disciplined investment pace while continuing to scale its presence in European and global life sciences.
Leadership, Team Developments and Governance
The firm highlighted its long standing relationships with major pharmaceutical companies and its internal bench of drug development specialists as key drivers of its performance. Co founders and Partners Francesco De Rubertis and Giovanni Mariggi emphasized that Medicxi has now raised six funds in the past decade, with cumulative commitments exceeding €2.0 billion. As part of the new fund, Medicxi promoted Shyam Masrani to Partner, recognizing his role in leading investments such as Merus and ProfoundBio, and confirmed that the investing partners for Fund V are De Rubertis, Mariggi, Nick Williams and Masrani.
With the launch of the €500 million Medicxi Fund V, the firm is reinforcing its commitment to a focused, asset driven model for biotech investing. Backed by a solid track record, growing capital base and expanded leadership team, Medicxi is positioned to support the next wave of drug hunters and entrepreneurs across the biotechnology sector. The firm’s stated objective is to translate cutting edge science into transformative therapies that deliver measurable impact for patients and healthcare systems worldwide.